As we reported here, Momenta is appealing a PTAB decision upholding the patentability of BMS’s U.S. Patent No. 8,476,239 (“the ’239 patent”), which relate to BMS’s Orencia® (abatacept) product.
Shares in Bristol-Myers Squibb were given a nudge after US regulators accepted an application to expand the use of its immunotherapy Opdivo in lung cancer. Shares in Bristol-Myers Squibb were given a ...
Bristol-Myers Squibb’s drive to build its Opdivo immunotherapy franchise continues, this time with a new FDA filing to treat melanoma in an earlier setting. BMS has asked the FDA for a licence to ...
Bemis Co Inc (BMS) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Bemis Co Inc operates in the packaging industry. The company engages in the manufacture of packaging ...
US regulators have accepted Bristol-Myers Squibb’s application to market its immunotherapy Opdivo plus Yervoy for the treatment of first-line advanced non-small cell lung cancer (NSCLC) in certain ...
Bristol-Myers Squibb’s drive to build its Opdivo immunotherapy franchise continues, this time with a new FDA filing to treat melanoma in an earlier setting. BMS has asked the FDA for a licence to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback